Icon PLC

The U.S. biotechnology and pharmaceutical services outsourcing market was valued at USD 10.18 billion in 2023, expected to reach USD 16.68 billion by 2033, growing at a CAGR of 5.06%. Pharmaceutical companies held the highest market share of 57.16% in 2023, while biotech companies are projected to grow at a CAGR of 5.4%. Consulting services dominated with a 24.96% revenue share in 2023, and product design & development is expected to grow at a CAGR of 4.19%. Market growth is driven by outsourcing in clinical trials, drug development, and research, along with cost-effective services and changing regulatory landscapes.

The clinical trial imaging market is projected to grow from USD 1.42 billion in 2024 to USD 2.07 billion by 2029, driven by increased R&D funding and the rise of CROs, despite high imaging costs. Services dominate the market, with computed tomography leading among imaging modalities. North America leads in market share, while emerging economies like India and China offer significant growth opportunities. Key players include ICON plc, Clario, and IXICO.

Precision Medicine Group appoints Margaret Keegan as CEO, succeeding Mark Clein who becomes Executive Chairman. Co-founders Clein and Ethan Leder remain on the Board. Precision, founded in 2012, specializes in drug development and commercialization services.

The global pharmaceutical CRO market is projected to grow from USD 43.13 Billion in 2024 to USD 81.51 Billion by 2033, driven by the complexity of clinical trials, technological advancements, and increasing R&D costs. Key segments include clinical, pre-clinical, small and large molecule types, and therapeutic areas like oncology and immunology. Major players include IQVIA, Medpace, and Thermo Fisher Scientific Inc.

SkyQuest projects the Clinical Trials Market to reach USD 102.12 Billion by 2031, with a CAGR of 8.7% from 2024-2031, driven by rising chronic diseases and personalized therapies.

The Virtual Clinical Trials Market is projected to grow from USD 2.64 billion in 2023 to USD 7.11 billion by 2029, at a CAGR of 17.95%. Key drivers include breaking barriers in women's health studies, integration of advanced systems, and a more patient-centric approach. Challenges include ethical considerations and regulatory compliance. The market is segmented by study type, phases, company size, and therapeutic area, with North America leading in adoption.

The Virtual Clinical Trials Market is expected to grow from USD 2.64 billion in 2023 to USD 7.11 billion by 2029, at a CAGR of 17.95%. Key trends include breaking barriers in women's health studies, integration of advanced systems, and a more patient-centric approach. Challenges include ethical considerations and regulatory compliance. North America leads in market dominance.

The Oncology Clinical Trial Market is projected to grow from USD xx.x Billion in 2023 to USD xx.x Billion by 2031, driven by increasing cancer prevalence, technological advancements, and regulatory support. Key manufacturers include IQVIA, Charles River Laboratory, ICON Plc, and others. Challenges include regulatory complexities and high costs. Opportunities exist in real-world evidence and novel trial designs.

The global cell and gene therapy clinical trials market was valued at USD 11.62 billion in 2023 and is projected to reach USD 47.40 billion by 2033, growing at a CAGR of 15.09%. Factors driving growth include a favorable regulatory environment, increasing interest in cancer treatments, patient demand for innovative therapies, and rising R&D funding. North America leads with a 49.76% share, while Asia Pacific is expected to grow fastest at a CAGR of 15.7%. The oncology segment dominates with a 49.1% share.